Novel expression of microRNAs in serum samples of Iraqi breast cancer women

Print Friendly, PDF & Email

[Limited Access]                   Full Text-PDF

American Journal of BioMedicine  Volume 2, Issue 5, pages 567–574, May 2014

Zaynab Saad; Muhammed Arif; Nahi Yassen;  Hameed Jasim; Majed Jelawe; James Brown


Although a lot of hard work against cancer to reduces its spread but it still continues to kill with abandon. The need for a biomarker for cancer early detection becomes the most mind concentrated scientists. MicroRNAs the tiny non coding RNA molecules opened new path for the scientists to determine the cancer in its early stages. Expression of microRNAs profiles has been investigated to be involved in cancer development. Here we determined the expression of microRNAs in serum of Iraqi healthy volunteers and other women diagnosed with breast cancer. MicroRNAs expression has been determined by using real time qPCR and delta method has been used. Four of thirteen microRNAs were shown to be expressed in serum of Iraqi breast cancer women. Let-7a and miR-21 were shown to be significantly over expressed in serum of breast cancer compared with healthy serum volunteers (= 0.022 and 0.026) respectively. While miR-26b and miR-429 found to be significantly down expressed in serum of breast cancer women (= 0.0034 and 0.031) respectively. The result concluded that these expressed microRNAs in serum of breast cancer women could be used as a first indicator of breast cancer occurrence.

Keywords: microRNA; Breast cancer; Real Time PCR; Reverse Transcription


1.  Jain S. Malignant: How cancer become us. University of California Press 2013.

2.  Iraqi Cancer Board. Results of Iraqi Cancer Registry 2004-2005. Ministry of Health. Baghdad-Iraq, 2010.

3.  Alex A. Novel anticancer agents: strategies for discovery and clinical testing. Chapter 10: Surrogate end points and bomarkers for early trails of novel anticancer agents. Academic Pr./ USA, 2006.

4.  Rosenfeld N, Aharonov R, Meiri E, Rosenwald S, Spector Y, Zepeniuk M, Benjamin H, et al MicroRNAs accurately identify cancer tissue origin. Nat. Biotechnol 2008; 26:462-469. [PubMed]

5.  Ambros V. The functions of animal microRNAs. Nature 2004; 431: 350-355. [PubMed]

6.  Cimmino A, Calin G, Fabbri M, Iorio M, Ferracin M, Shimizu M, et al.  MiRNA-15 and miRNA-16 induce apoptosis by targeting BCL2. Proc. Natl. Acad. Sci. USA 2005; 102: 13944-13949. [Abstract/Full-Text]

7.  Kim V, Nam J. Genomics of miRNA. TRENDS in Genetics 2006; 22: 165. [Abstract/Full-Text]

8.  Cortez M, Bueso-Ramos C, Ferdin J, Sood A, Calin G.  MicroRNAs in body fluids- the mix of hormones and biomarkers. Rat. Rev. Clin. Oncol 2011; 8:467-477. [PubMed]

9.  Kantarjian H, Wolff R, Koller C. The MD Anderson Manual of Medical Oncology. 2nd ed. McGrawHill Medical Inc. US, 2011.

10.  Lee R, Feinbaum R, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complemetarity to lin-14. Cell 1993;75: 843-854. [Abstract/Full-Text]

11.  Mitchell PS, Parkin R, Kroh E, Fritz B, Wyman S, et al. Circulating miRNAs as stable blood- based markers for cancer detection. Proc. Natl. Acad. Sci. USA 2008; 105: 10513-10518. [Abstract/Full-Text]

12.  Krol J, Loedige I, Filipowicz W. The wide separed regulation of microRNA biogenesis, function and decay. Nature Rev. Genet 2010; 11:579-610. [Abstract/Full-Text]

13.  Chim SS, Shing TK, Hung EC, Leung TY, Lau TK, Chiu RW, Lo YM. Detection and charachterization of placental microRNA in maternal plasma. Clin. Chem 2008; 54:482-490. [PubMed]

14.  Heneghan H, Miller N,  Kelly R, Newell J. Systemic miR-195 diffrentiate breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. Oncologist 2010; 15: 673-682.  [Abstract/Full-Text]

15.  Marc E, Jean-Pierre D, Thierry C. Breast cancer incidence and hormone replacement therapy: Results from mission study, prospective phase. J. Gyne. Endo  2007; 23: 391-397.

16.  Zhang H, Li Y, Lai M. The microRNA network and tumor metastasis. Oncogene 2010; 29: 937-948.  [Abstract/Full-Text]

17.  Gao J, Zhang Q, Guo L, Xu J. Clinical Significance of serum miR-21 in breast cancer compared with CA15-3 and CEA. Chin. J. Cancer Res 2013; 25:743-748. [Abstract/Full-Text]

18.  Li J, Kong X, Zhang J, Luo Q, Li X. MiRNA-26b inhibits proliferation by targeting PTGS2 in breast cancer. Ca. Cell Int 203;13:7. [PubMed]

19.  Gao J, Liu Q. The role of miR-26 in tumors and normal tissues (review). Oncol. Lett 2011; 2:1019-1023. [Abstract/Full-Text]

20.  Burk U, Schubert J, Wellner V, Schmalhofer O, Brabletz T. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep 2008; 9:582-589. [Abstract/Full-Text]

21.  Park S, Gaur A, Lengyel E, Peter M. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1and  ZEB2. Genes Dev 2008;22:894-907. [PubMed[Abstract/Full-Text]

22.  Hashimoto Y, Akiyama Y, Yuasa Y. Multiple-to-multiple relation ships between miRNAs and targets genes in gastric cancer. PLoS One 2013;8: e62589. [Abstract/Full-Text]

23.  Wang G, Tam L, Li E. Serum and Urinary free miRNA levels in pateints with systemic lupus erythematosus. Lupus 2011; 20:493-500. [Abstract/Full-Text]